Search

Your search keyword '"Gérard Zalcman"' showing total 414 results

Search Constraints

Start Over You searched for: Author "Gérard Zalcman" Remove constraint Author: "Gérard Zalcman"
414 results on '"Gérard Zalcman"'

Search Results

401. Preliminary results of a randomized study comparing the efficacy of 2 doses of docetaxel 100 mg/m2/3 weeks vs 75 mg/m2/3 weeks in treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of a previous cis-platin based chemotherapy

402. Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group

403. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort

404. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein

405. A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

406. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas

407. Cost-utility analysis of maintenance therapy with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502-eco phase III study

408. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study

409. Retrospective observational study of diagnostic accuracy of the Xpert® MTB/RIF assay on fiberoptic bronchoscopy sampling for early diagnosis of smear-negative or sputum-scarce patients with suspected tuberculosis

410. Hippo signaling contribution to the natural history of Malignant Pleural Mesothelioma (MPM) : its roles in human pleural mesothelial cells lines and application to the molecular characterization of the 448 patients with MPM included in the phase 3 clinical trial ' MAPS '

412. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

413. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

414. Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.

Catalog

Books, media, physical & digital resources